Karyopharm Therapeutics Inc. (KPTI) is a publicly traded Healthcare sector company. As of September 11, 2026, KPTI trades at $1.49 with a market cap of $38.33M and a P/E ratio of -0.11. KPTI moved -3.09% today. Year to date, KPTI is -77.47%; over the trailing twelve months it is -73.91%. Its 52-week range spans $1.60 to $10.99. Analyst consensus is buy with an average price target of $6.54. Rallies surfaces KPTI's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks KPTI insider trades, Form 4 activity, executive purchases, executive sales, shares, prices, and transaction dates when available.
| Metric | Value |
|---|---|
| Price | $1.49 |
| Market Cap | $38.33M |
| P/E Ratio | -0.11 |
| EPS | $-14.16 |
| Dividend Yield | 0.00% |
| 52-Week High | $10.99 |
| 52-Week Low | $1.60 |
| Volume | 2.09M |
| Avg Volume | 0 |
| Revenue (TTM) | $146.62M |
| Net Income | $-224.74M |
| Gross Margin | 0.00% |
6 analysts cover KPTI: 0 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $6.54.